Gregory Rossi, PhD

home / authors / gregory-rossi-phd

Articles

Clinical Trial Simulation of a 200-µg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia

Nelson Jumbe, PhD;Bin Yao, MS;Gregory Rossi, PhD;Anne C. Heatherington, PhD

October 1st 2002

Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic

Darbepoetin Alfa: Impact on Treatment for Chemotherapy-Induced Anemia and Considerations in Special Populations

Johan Vansteenkiste, MD, PhD;Erik Poulsen, MS;Gregory Rossi, PhD;John Glaspy, MD, MPH

October 1st 2002

Our objective was to evaluate the effects of darbepoetin alfa (Aranesp) on hemoglobin and transfusions in anemic patients with cancer undergoing chemotherapy, and the impact of age, sex, baseline hemoglobin, chemotherapy

Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia

Barry Mirtsching, MD;Veena Charu, MD;Saroj Vadhan-raj, MD;Alan B. Colowick, MD, MPH;Gregory Rossi, PhD;Dianne Tomita, MPH;William P. Mcguire Iii, MD

October 1st 2002

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by